Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma

  title={Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma},
  author={Corrado Pelaia and Giulia Pelaia and Federico Longhini and Claudia Crimi and Cecilia Calabrese and Luca Gallelli and Angela Sciacqua and Alessandro Vatrella},
Alarmins are innate cytokines, including thymic stromal lymphopoietin (TSLP), interleukin-33 (IL-33), and interleukin-25 (IL-25), which are mainly produced by airway epithelium and exert a prominent role in asthma pathobiology. In particular, several environmental factors such as allergens, cigarette smoking, airborne pollutants, and infectious agents trigger the release of alarmins, which in turn act as upstream activators of pro-inflammatory pathways underlying type 2 (T2-high) asthma. Indeed… 

Figures and Tables from this paper

Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors
Whether treatment with biological agents and JAK inhibitors may be equally effective in controlling type 2 inflammatory process in both asthma and CRS is discussed.
Involvement of Il-33 in the Pathogenesis and Prognosis of Major Respiratory Viral Infections: Future Perspectives for Personalized Therapy
This work analyzed the pathogenetic and prognostic involvement of IL-33 during the main respiratory viral infections, with particular interest in the recent SARS-CoV-2virus pandemic and the aim of determining a possible connection point on which to act with a targeted therapy that is able to improve the clinical outcome of patients.
Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis
A network meta-analysis to compare and rank the efficacy of five treatments for asthma in overall participants and in subgroups stratified by the thresholds of type 2 inflammatory biomarkers provided a basis for the development of treatment strategies for asthma.
Crosstalk between ILC2s and Th2 CD4+ T Cells in Lung Disease
The latest progress on ILC2s and CD4+T cells in the lung, the close relationship between the two, and their relevance inThe lung disease and immunity are reviewed to aid future research in pulmonary type 2 immune diseases and guides innovative treatment approaches for these diseases.


Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma
Systemic anti-TSLP monoclonal antibody therapy with tezepelumab has yielded positive results in clinical trials to date, reducing exacerbations and biomarkers of inflammation in patients across the spectrum of inflammatory endotypes.
Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
Preliminary results of randomized clinical trials suggest that tezepelumab is characterized by a good safety and efficacy profile in patients with severe, uncontrolled asthma.
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics
Blocking epithelial alarmins, upstream mediators triggered early in the asthma inflammatory response that orchestrate broad inflammatory effects, is a promising alternative approach to asthma treatment, which may be effective in a broad patient population.
Anti-TSLP antibodies: Targeting a master regulator of type 2 immune responses.
IL33: Roles in Allergic Inflammation and Therapeutic Perspectives
This review focuses on the recent advances of the underlying intercellular and intracellular mechanisms by which IL-33 can regulate the allergic inflammation in various allergic diseases including allergic asthma and atopic dermatitis.
TSLP Inhibitors for Asthma: Current Status and Future Prospects
Some critical aspects remain to be clarified before being able to define this approach as the one that will probably better help patients suffering from severe asthma because of its holistic effects, but new information suggests that targeting TSLP may be more likely to improve day-to-day asthma symptoms.
Molecular Targets for Biological Therapies of Severe Asthma
New therapeutic options make it possible to implement phenotype/endotype-specific treatments, that are delineating personalized approaches precisely addressing the individual traits of asthma pathobiology, allowing to successfully target the immune-inflammatory responses underlying uncontrolled T2-high asthma.
Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma
A fusion protein comprising a tandem of the TSLPR and IL-7Rα extracellular domains is introduced, which harnesses the mechanistic intricacies ofThe TSLP-driven receptor complex to manifest high antagonistic potency.
Epithelial cell–derived cytokines: more than just signaling the alarm
An overview of TSLP, IL-33, and IL-25 and the development of blocking antibodies that target these epithelial cell–derived cytokines is provides an overview of these central regulators of type 2 immunity.
Role of IL‐25, IL‐33, and TSLP in triggering united airway diseases toward type 2 inflammation
This work reviews studies that elucidated the role of epithelium‐derived triple cytokines in both upper and lower airways with the purpose of expediting better clinical treatments and managements of AR, CRS, asthma, and other associated allergic diseases via applications of the modulators of these cytokines.